- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07493304
고형암 및 혈액암 성인 참가자의 정맥 혈전색전증(VTE) 치료 및 이차 예방 (ROXI-CAT-II)
고형 및 혈액암 환자에서 정맥 혈전색전증의 치료 및 2차 예방을 위한 Factor XI 단일클론항체 REGN7508의 유효성 및 안전성을 평가하는 2부작, 3상, 다기관, 무작위, 개방형, 능동 대조군 연구 (ROXI-CAT-II)
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis [DVT]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism [PE]) (Part 2).
The aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban).
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Administrator
- 전화번호: 844-734-6643
- 이메일: clinicaltrials@regeneron.com
연구 장소
-
-
-
Busan, 대한민국, 48108
- 모병
- Inje University, Haeundae Paik Hospital
-
Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center
-
Seoul, 대한민국, 3080
- 모병
- Seoul National University Hospital
-
Seoul, 대한민국, 03722
- 모병
- Yonsei University Health System, Severance Hospital
-
-
Gyeonggi-do
-
Yongin-si, Gyeonggi-do, 대한민국, 16995
- 모병
- Yonsei University Health System, Yongin Severance Hospital
-
-
-
-
Bucharest
-
Bucharest, Bucharest, 루마니아, 022328
- 모병
- Institute of Oncology Bucharest
-
-
Cluj
-
Cluj-Napoca, Cluj, 루마니아, 400015
- 모병
- Arensia Exploratory Medicine, The Oncology Institute "Prof. Dr. Ion Chiricuta"
-
-
-
-
Florida
-
Hialeah, Florida, 미국, 33013
- 빼는
- Bioresearch Partner- Hialeah Hospital
-
-
New York
-
New York, New York, 미국, 10021
- 모병
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, 미국, 79902
- 빼는
- El Paso Medical Research Institute (Medresearch Inc)
-
-
-
-
-
Sofia, 불가리아, 1618
- 모병
- Arensia Exploratory Medicine, Multiprofile Hospital for Active Treatment Sveta Sofia
-
-
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, 일본, 259-1193
- 모병
- Tokai University Hospital
-
-
Tokyo
-
Shinjuku, Tokyo, 일본, 160-0023
- 모병
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, 일본, 755-8505
- 모병
- Yamaguchi University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
-
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 at the time of screening and day 1 prior to first dose of study intervention
-
In Part 1 participants with cancer and Part 2 participants: Histologically confirmed diagnosis of malignant solid or select hematologic tumor (other than basal-cell or squamous-cell carcinoma of the skin alone) as described in the protocol
-
Part 1 additional criteria:
- Has newly diagnosed symptomatic lower extremity DVT or incidentally-detected proximal lower extremity DVT (eg, popliteal or femoral) within 5 days (120 hours) of randomization (with imaging confirmation)
- Anticoagulation therapy with a therapeutic dose of a Direct Oral Anticoagulant (DOAC) for at least 3 months is indicated for the newly diagnosed proximal lower extremity DVT
-
Part 2 additional criteria:
- Newly diagnosed VTE within 5 days (120 hours) of randomization (with imaging confirmation) as described in the protocol
- Anticoagulation therapy with a therapeutic dose of a DOAC for at least 6 months is indicated for newly diagnosed VTE
Key Exclusion Criteria:
-
Is at high risk of intracranial bleeding in the opinion of the investigator
-
Known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
-
Contraindication to anticoagulation in the opinion of the investigator
-
Life expectancy of < 6 months
-
Part 1 participants with cancer and Part 2 additional exclusion criteria:
- Has acute leukemia or myelodysplastic syndrome
- Has primary brain tumor
- Has brain metastases as described in the protocol
-
Part 1 additional exclusion criteria:
- Has a symptomatic PE
- Has an asymptomatic (incidentally-diagnosed) PE in a segmental or larger pulmonary artery
-
Part 2 additional exclusion criteria: PE leading to hemodynamic instability as described in the protocol
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: 아픽사반
|
Administered per the protocol |
|
실험적: REGN7508
|
Administered per the protocol
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
기간: Approximately 6 months
|
Part 1 |
Approximately 6 months
|
|
Severity of TEAEs
기간: Approximately 6 months
|
Part 1 |
Approximately 6 months
|
|
Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent inhibition of Factor XI functional Coagulant activity (FXI:C)
기간: Approximately 3 months
|
Part 1 |
Approximately 3 months
|
|
Fold change from baseline in activated Partial Thromboplastin Time (aPTT)
기간: Approximately 3 months
|
Part 1 |
Approximately 3 months
|
|
Functional REGN7508 concentration
기간: Approximately 3 months
|
Part 1 |
Approximately 3 months
|
|
Factor XI (FXI) concentration
기간: Approximately 3 months
|
Part 1 |
Approximately 3 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
기간: Up to approximately 3.5 years
|
Part 1 and Part 2 |
Up to approximately 3.5 years
|
|
Magnitude of ADA to REGN7508
기간: Up to approximately 3.5 years
|
Part 1 and Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first centrally adjudicated event of DVT (symptomatic or asymptomatic [proximal])
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first centrally adjudicated event of Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery])
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first centrally adjudicated event of VTE-related death
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first event of centrally adjudicated venous thromboembolic events other than DVT and PE
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first event of centrally adjudicated Arterial Thromboembolism (ATE)
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Time-to-first event of centrally adjudicated recurrent VTE and bleeding events [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic) or VTE-related death) or bleeding (ISTH-defined major bleeding or CRNM bleeding)]
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Occurrence of TEAEs
기간: Up to approximately 3.5 years
|
Part 2 |
Up to approximately 3.5 years
|
|
Severity of TEAEs
기간: Up to 3.5 approximately years
|
Part 2 |
Up to 3.5 approximately years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trial Management, Regeneron Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- R7508-CAT-2396
- 2024-519299-16-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 공유 기간
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 공유 액세스 기준
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .